Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Advanced Solid Tumor 12Solid Tumor 5Nasopharyngeal Carcinoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Sarcoma 2Recurrence 2Neoplasms 2Locally Advanced or Metastatic Solid Tumors 2Liposarcoma 2Advanced Solid Tumors 2Advanced Lung Cancer 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor, Adult 1Solid Cancer 1Small Cell Lung Carcinoma 1Pyloric Stenosis, Hypertrophic 1Pancreatic Neoplasms 1Pancreatic Cancer Metastatic 1PD-1 1Ovarian Neoplasms 1Meningeal Carcinomatosis 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Leiomyosarcoma 1

Interventions

Carboplatin 46Paclitaxel 31pembrolizumab 25Cyclophosphamide 24Nivolumab 14Bevacizumab 14Topotecan 12Gemcitabine 12liposomal doxorubicin 11Filgrastim 11Cisplatin 11fludarabine 10Peripheral Blood Stem Cell Transplantation 10olaparib 8aldesleukin 7durvalumab 6Oxaliplatin 6Ipilimumab 6Interleukin-2 6Docetaxel 6niraparib 5epacadostat 5cemiplimab 5Ifosfamide 5Fulvestrant 5rucaparib 4poly ICLC 4pazopanib 4avelumab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Ovarian Neoplasms × toripalimab × Clear all
NCT05955105 2024-05-21

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Innolake Biopharm

Phase 1/2 Recruiting
200 enrolled
BreastDermatologicGynecologicHead & NeckSarcomaThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡